Skip to main content

Table 2 Baseline information - Mild Cognitive Impairment (MCI)

From: Association of modifiable risk factors with progression to dementia in relation to amyloid and tau pathology

Amyloid

n

All (n = 611)

Amyloid positive (n = 377)

Amyloid negative (n = 234)

statistics

Age: mean (SD) years

610

72.5 ( 7.4)

73.5 ( 6.8)

70.9 ( 8.1)

t = -4.0,df = 481.4,p = < .0001 *

Baseline MMSE

611

27.8 ( 1.8)

27.4 ( 1.8)

28.4 ( 1.5)

t = 8.2,df = 630.7,p = < .0001 *

ApoE4 carrier status

611

300 ( 49.1%)

246 ( 65.3%)

54 ( 23.1%)

ChiSq = 102.8,df = 1.0,p = < .0001 *

Baseline Hippocampus Volume (mm3)

611

6865 (1133)

6631 (1064)

7242 (1142)

t = 6.6,df = 474.7,p = < .0001 *

Female gender: n (%)

611

255 ( 41.7%)

156 ( 41.4%)

99 ( 42.3%)

ChiSq = 0.1, df = 1.0, p = 0.8210

Higher CAIDE score: n (%)

606

223 ( 36.8%)

141 ( 37.8%)

82 ( 35.2%)

ChiSq = 0.4, df = 1.0, p = 0.5172

CAIDE Total Score

606

5.9 ( 1.4)

5.8 ( 1.4)

5.9 ( 1.5)

t = 0.8, df = 543.7, p = 0.4211

Depression as risk: n (%)

611

192 ( 31.4%)

110 ( 29.2%)

82 ( 35.0%)

ChiSq = 2.3, df = 1.0, p = 0.1290

Smokers: n (%)

576

70 ( 12.2%)

48 ( 13.5%)

22 ( 10.0%)

ChiSq = 1.5, df = 1.0, p = 0.2138

Follow-up time: median(IQR)

611

48 ( 30- 78)

48 ( 24- 60)

48 ( 36- 96)

ChiSq = 17.8,df = 1.0,p = < .0001 *

Progression to dementia: n(%)

611

221 ( 36.2%)

195 ( 51.7%)

26 ( 11.1%)

ChiSq = 103.2,df = 1.0,p = < .0001 *

p-tau181

n

All (n = 551)

p-tau181 positive (n = 305)

p-tau181 negative (n = 246)

statistics

Age: mean (SD) years

551

72.4 ( 7.5)

73.4 ( 7.4)

71.1 ( 7.4)

t = -3.4,df = 563.7,p = 0.0007 *

Baseline MMSE

551

27.7 ( 1.8)

27.4 ( 1.8)

28.1 ( 1.7)

t = 5.2,df = 578.7,p = < .0001 *

ApoE4 carrier status

551

273 ( 49.5%)

192 ( 63.0%)

81 ( 32.9%)

ChiSq = 49.1,df = 1.0,p = < .0001 *

Baseline Hippocampus Volume (mm3)

551

6820 (1150)

6582 (1077)

7116 (1171)

t = 5.5,df = 504.2,p = < .0001 *

Female gender: n (%)

551

230 ( 41.7%)

132 ( 43.3%)

98 ( 39.8%)

ChiSq = 0.7, df = 1.0, p = 0.4155

Higher CAIDE score: n (%)

548

196 ( 35.8%)

102 ( 33.7%)

94 ( 38.4%)

ChiSq = 1.3, df = 1.0, p = 0.2534

CAIDE Total Score

548

5.8 ( 1.4)

5.7 ( 1.3)

6.0 ( 1.5)

t = 2.2, df = 522.8, p = 0.0309

Depression as risk: n (%)

551

183 ( 33.2%)

90 ( 29.5%)

93 ( 37.8%)

ChiSq = 4.2, df = 1.0, p = 0.0398

Smokers: n (%)

551

68 ( 12.3%)

41 ( 13.4%)

27 ( 11.0%)

ChiSq = 0.8, df = 1.0, p = 0.3814

Follow-up time: median(IQR)

551

48 ( 36- 84)

48 ( 36- 66)

48 ( 36- 90)

ChiSq = 12.6,df = 1.0, p = 0.0004 *

Progression to dementia: n (%)

551

213 ( 38.7%)

163 ( 53.4%)

50 ( 20.3%)

ChiSq = 63.0,df = 1.0,p = < .0001 *

Amyloid and p-tau181

n

All (n = 418)

Amyloid and p-tau181 positive (n = 257)

Amyloid and p-tau181 negative (n = 160)

statistics

Age: mean (SD) years

417

72.1 ( 7.6)

73.4 ( 7.1)

69.9 ( 7.8)

t = -4.4,df = 343.3, p = < .0001 *

Baseline MMSE

417

27.7 ( 1.8)

27.3 ( 1.8)

28.4 ( 1.5)

t = 7.3,df = 419.3, p = < .0001 *

ApoE4 carrier status

417

213 ( 51.1%)

177 ( 68.9%)

36 ( 22.5%)

ChiSq = 84.9,df = 1.0, p = < .0001 *

Baseline Hippocampus Volume (mm3)

417

6763 (1142)

6477 (1026)

7221 (1174)

t = 6.6,df = 303.4, p = < .0001 *

Female gender: n (%)

417

184 ( 44.1%)

113 ( 44.0%)

71 ( 44.4%)

ChiSq = 0.0, df = 1.0, p = 0.9353

Higher CAIDE score: n (%)

414

144 ( 34.8%)

88 ( 34.5%)

56 ( 35.2%)

ChiSq = 0.0, df = 1.0, p = 0.8827

CAIDE Total Score

414

5.8 ( 1.4)

5.7 ( 1.3)

5.9 ( 1.6)

t = 1.3, df = 332.2, p = 0.2014

Depression as risk: n (%)

417

144 ( 34.5%)

78 ( 30.4%)

66 ( 41.3%)

ChiSq = 5.2, df = 1.0, p = 0.0228

Smokers: n (%)

417

45 ( 10.8%)

33 ( 12.8%)

12 ( 7.5%)

ChiSq = 2.9, df = 1.0, p = 0.0874

Follow-up time: median(IQR):

417

48 ( 36- 78)

48 ( 36- 60)

60 ( 36- 96)

ChiSq = 20.7,df = 1.0, p = < .0001 *

Progression to dementia: n (%)

417

178 ( 42.7%)

158 ( 61.5%)

20 ( 12.5%)

ChiSq = 96.7,df = 1.0, p = < .0001 *

  1. CU Cognitively Unimpaired, MCI Mild Cognitive Impairment, MMSE Mini-Mental State Examination, ApoE4 Apolipoprotein E epsilon 4 carriers, CAIDE Cardiovascular Risk Factors, Aging, and Dementia, p-tau181 Phosphorylated tau 181, CSF Cerebrospinal Fluid, n Number of participants, SD Standard Deviation, IQR Interquartile Range, ChiSq Chi-Square Test, df Degrees of Freedom, p p-value
  2. *p-values indicate significant differences between biomarker positives and negatives (after correction for multiple comparisons p < 0.05/11, where 11 is the number of parameters compared), and are based on T-tests or Wilcoxon tests (follow-up time) in case of continuous variables and Chi-Square tests in case of categorical variables
Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193